DOCSLIB.ORG

12151 Premier Healthcare AD2 2019 07 01.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
12151 Premier Healthcare AD2 2019 07 01.Pdf 12151M ADDENDUM OF AGREEMENT THIS ADDENDUM, made and entered into effective as of the date by which both parties hereto have executed this document, by and between the County of Dane (hereinafter referred to as "County") and Premier Healthcare Alliance LP hereinafter, "Provider"). WITNESSETH: WHEREAS Provider and County, by a separate document (hereinafter, the "Master Agreement"), Purchase of Services Agreement No. 12151, have previously entered into a contractual relationship with Provider for the purpose of gaining access to Provider's group purchasing program for pharmaceuticals, medical equipment and supplies and related products and services to provide a means for County's Badger Prairie Health Care Center and other County departments or agencies to procure pharmaceuticals, medical equipment and supplies and related products and services at a reduced cost through group purchasing, and WHEREAS County and Provider wish to amend the Master Agreement in order to replace Appendix 1: List of Premier Suppliers as of 07/01/2019. NOW, THEREFORE, in consideration of the above premises and the mutual covenants of the parties hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged by each party for itself, the parties do agree as follows: 1. The Master Agreement shall remain in full force and effect unchanged in any manner by this addendum except as changes are expressly set forth herein. This addendum shall control only to the extent of any conflict between the terms of the Master Agreement and this addendum. 2. Appendix 1: List of Premier Suppliers dated 04/01/2019 is replaced in full by Appendix 1: List of Premier Suppliers dated 07/01/2019. IN WITNESS WHEREOF, the parties, by their respective authorized representatives, have set their hands and seals as of the dates set forth below. FOR~ . Date Signed: 7.,.. / (11-17 r.o~ Date Signed: _____ FOR PROVIDER: Date Signed: 07/11/19 Page 1 of 20 12151M 2G Medical, LLC. 3 West Medical 3M Company A&E Medical Corporation Abbott Laboratories, Inc. Abbott Nutrition Abbott Vascular Devices AbbVie US LLC Access Scientific Inc Accord Healthcare Inc AccuVein LLC ACell Inc. Acella Pharmaceuticals, LLC Acist Medical Systems Acquire Med LLC Action Health Acute Care Pharmaceuticals Adapt Pharma ADMA Biologics, Inc. Adroit Medical Systems Inc Advance Medical Designs, Inc. Advanced Vascular Dynamics Aesculap, Inc. Agamatrix Inc Agfa US Corp. Agiliti Health, Inc. Airgas, Inc. Airpal Inc Akorn Inc Alcon Laboratories Inc Alembic Pharmaceuticals, Inc. Alimed, Inc. Alkermes Inc Allcare, Inc. Allergan USA Inc Alliance Laboratories Alliance Tech Medical, Inc. Alliant Healthcare Allied Healthcare Products, Inc. Almatica Pharma Inc Alvogen, Inc Page 2 of 20 12151M AMAG Pharmaceuticals Inc Ambler Surgical, LLC. Ambu, Inc. Amd-Ritmed, Inc. American Contract Systems American Diagnostic Corp. American Green Technology, Inc. American Health Packaging American Medical Depot American Regent, Inc. American Textile Systems AmerisourceBergen Drug Corporation Amgen Inc. Amico Corporation Amneal Biosciences LLC Amneal Pharmaceuticals, LLC Amniox Medical, Inc. Amoena Amphastar Pharmaceuticals, Inc. Amring Pharmaceuticals, Inc. Andover Healthcare Inc Angiodynamics Inc ANI Pharmaceuticals Ansell Healthcare Products Inc Ansell Sandel Medical Solutions Apollo Endosurgery Apotex Corp. Applied Medical Resources Corporation Arbor Pharmaceuticals Inc Arc Medical Areva Pharmaceuticals Arjo Inc. Arkray USA Arabella Medical Inc Arrow International Inc Artelon, LLC. Artemax ARUP Laboratories Asahi lntecc USA Aseptic Enclosures Aspen Surgical Products, Inc. Astellas Pharma US, Inc. Astrazeneca Pharmaceuticals LP Page 3 of 20 12151M Athenex Pharmaceutical Division, LLC Atom Medical USA, LLC Attain Med, Inc. Attune Medical Augustine Temperature Management Aurobindo Pharma Usa, Inc. AuroMedics Pharma LLC Avadel Legacy Pharmaceuticals, Inc. Avadim Technologies Avancen MOD Corporation Avanos Medical, Inc. Avkare Inc. AxisCare Health Logistics, Inc. Azer Scientific B. Braun lnterventional Systems Inc. B. Braun Medical, Inc. Bacterin International Inc Baker Company, The Bard Access System Bard Medical Division Bard Peripheral Vascular Inc Bausch & Lomb Surgical, Inc. Bausch Health US, LLC Baxalta US Inc. Baxter Healthcare Corporation Bayer HealthCare Bayshore Pharmaceuticals LLC BDI Pharma Beaver Visitec International Inc Beckman Coulter Inc Becton, Dickinson and Company Belimed, Inc. Besse Medical Best Medical International, Inc. Betco Beutlich Pharmaceuticals, LLC Bio Products Laboratory Biocare BioComp Pharma, Inc BioDelivery Sciences International, Inc. BioDerm, Inc bioMerieux, Inc. Bionpharma, Inc. Page 4 of 20 12151M Bio-Rad Laboratories Biotronik, Inc. Bioventus LLC Biovigil Healthcare Systems, Inc. Birchwood Laboratories Inc Blickman Industries Blue Ridge X-Ray Co Inc Boehringer lngelheim Pharmaceuticals, Inc. Boehringer Laboratories, LLC Boss Instruments, Ltd. Boston Medical Products, Inc. Boston Scientific Corporation BPI Labs, LLC BPI Medical, Inc. Bracco Diagnostics, Inc. Braintree Laboratories Inc Brasseler USA Breckenridge Pharmaceutical Inc. Breg, Inc Brewer Company, LLC Bristol Myers Squibb US Pharm Bryton Corporation BSN Medical, Inc. BTG International Inc. BTNX, Inc. Buckeye International, Inc. Buffalo Filter Buffalo Hospital Supply Busse Hospital Disposables Cameron Pharmaceuticals, LLC Canon Medical Systems, USA, Inc. Capital Inventory, Inc. Capsa Solutions LLC Cardinal Health 200, LLC Cardinal Health 414, LLC Cardinal Health P.R. 120, Inc. Cardinal Health Speciality Pharmaceutical Services Care Line, Inc. CareandWear II, Inc. CareFusion 211, Inc. CareFusion 213, LLC CareFusion 2200, Inc. CareFusion 303, Inc. Page 5 of 20 12151M CareFusion Solutions, Inc. CarePICS Carestream Health Inc Carl Zeiss Meditec Carolina Medical Products Company Carolina Narrow Fabric Company Carolan Company Casco Manufacturing Solutions Inc Case Medical, Inc. Celularity Functional Regeneration, LLC Centrak Inc Central Admixture Pharmacy Services, Inc. Centurion Medical Products Cerapedics, Inc. Certol International, LLC Cesar Castillo Inc Cetylite Ind, Inc. Chiesi USA, Inc Christie Medical Holdings Inc Gianna Medical, Inc Cincinnati Sub-Zero Products, LLC Cipla, USA, Inc Circa Scientific Claflin Company Cleanis Inc ClearFlow Clinical Innovations, Inc. Clorox Sales Company Coherus BioSciences, Inc. Collegium Pharmaceutical Coloplast Corp. Compression Solutions, Inc Compression Therapy Concepts Conceivex, Inc. 663629 (P) Concordance Healthcare Solutions Conmed Corporation Conmed Linvatec ConsortiEX Inc. Consure Medical Contee ConvaTec Inc Cook Medical, LLC Cookgas, LLC Page 6 of 20 12151M Cooper-Atkins Corporation CooperSurgical, Inc. Cosmed USA Covalon Technologies AG Ltd. Covidien Sales LLC CPT Medical, Inc. Crosstex International, Inc. CSL Behring CTC Medical Repair, Inc Cumberland Pharmaceuticals Inc Cura Surgical Custom Medical Solutions CutisPharma Inc. Daiichi Sankyo, Inc. Dakota Drug, Inc. Dash PharmaceuticalsLLC Davol Inc. DeNovo Products LLC Derma Sciences, Inc. Deroyal Industries Inc Detecto Scale Co. Diagnostica Stago, Inc. Direct Surgical Equipment Diversey, Inc. DJO Global DMS Pharmaceutical Group, Inc. Dr. Reddy's Laboratories, Inc. Draeger, Inc. DRE Medical Equipment Drogueria Betances, Inc. Duracell Industrial Operations, Inc. Dynavax Technologies Corporation EM Adams Company, Inc. Eagle Pharmaceuticals, Inc ECI Pharmaceuticals, Inc. Ecolab, Inc. Edenbridge Pharmaceuticals LLC Edwards Lifesciences LLC Ehob, Inc. Eisai Corporation Of North America eKare Inc. Ekla Corporation Ekos Corporation Page 7 of 20 12151M Electro Medical Equipment Co. (EME) Electromed Inc Eli Lilly and Company Eli Lilly Exports S.A. Elkay Plastics Co., Inc. Encompass Group LLC Endo Pharmaceuticals Inc Energizer Battery Company Epic Pharma Espero Pharmaceuticals, Inc Essity Ethicon, Inc. Ethicon Endo-Surgery,inc. Evoke Neuroscience Exela Pharma Sciences, LLC EXP Pharmaceutical Services Corp. EZWay Inc Fagron US Federal Express Corporation Ferndale Laboratories, Inc. Ferring Pharmaceuticals, Inc. FFF Enterprises Fibertech Medical USA First Healthcare Products, Inc. Fisher & Paykel Healthcare, Inc. Fisher Scientific Healthcare Flexicare Inc. Focus Health Group Freedom Medical Inc Fresenius Kabi Fujifilm Medical Systems USA, Inc. Fukuda Denshi Usa, Inc. G & W Laboratories Inc GA International Inc Galen US Inc. GE Healthcare GE Healthcare Medical Diagnostics GE Medical Systems Information Technologies, Inc. Genadyne Biotechnologies GenDose Pharmaceuticals, LLC Genentech USA Inc Genicon, LLC Gensco Laboratories, LLC. Genus Lifesciences Page 8 of 20 12151M Genus Medical Technologies Georgia Pacific Consumer Products LP Geritrex, LLC Getinge USA Sales, LLC Glaxosmithkline Inc. Glenmark Pharmaceuticals Inc., USA GOJO Industries, Inc. Grace Medical, Inc. Graham Medical Great American Art Greenstone LLC Greenwood Marketing, Inc. Greiner Bio-One North America, Inc. Grifols Biological, Inc. Grifols Diagnostic Solutions Inc. GSK Consumer Guerbet Caribbean Inc. Guerbet LLC H D Smith, LLC H20RS, Inc Haemonetics Corp. Halosil International, Inc. Halozyme Therapeutics Hamilton Medical, Inc. Handicare USA Harris Pharmaceutical Inc Health o meter Professional HealthConnexx, LLC Healthmark Industries Co. HealthTrackRx Helmer, Inc. Helsinn Therapeutics (U.S.) HemoCue America Henry Schein, Inc. Heritage Bag Company Heritage Pharmaceuticals Inc Heron Therapeutics, Inc. Herzog Surgical Hikma Pharmaceutical USA Inc. Hill-Rom Company, Inc. Hilton Publishing
Load more

Recommended publications
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I
    Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I. Imaging Systems Corp A.L.I. Technologies (International) LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Division Abbott Nutrition Products Division Abbott Pharmaceutical Products Group Abbott Point of Care Division Abbott Vascular Division Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Advanced Neuromodulation Systems, Inc. Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Aesculap Implant Systems, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Alaven Pharmaceuticals, LLC 2260 Northwest parkway Suite A Marietta GA 30067 Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allen Medical Systems, Inc. Allergan Sales, LLC Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Alpharma Pharmaceuticals, Inc. Alpharma Pharmaceuticals, LLC AMAG Pharmaceuticals, Inc. 100 Hayden Avenue Lexington MA 02421 AMATECH Corporation American Medical Distributors, Inc. 100 New Highway N Amityville NY 11701 American Medical System,
    [Show full text]
  • 2020 Annual Report 2020 PARTNER of the YEAR 3 Annual Comparison SUSTAINED, CONSISTENT GROWTH
    Greater Together Annual Report 2020 Greater Together The emergence of the COVID-19 pandemic led to unprecedented challenges for the global healthcare industry in 2020, and West played a vital role in the race to deliver an effective vaccine for the virus. CUSTOMERS: OUR PARTNERS Through these challenging times, vaccine developers have trusted West as a partner of choice to help protect their sensitive biomolecules. This is a testament to West’s almost 100 years of experience and reputation for leadership in quality. We have met these high expectations through our ability to flex our operations within our global network to meet supply needs. These customers were seeking components to support the development work, clinical trials, and potentially post-approval launches, and we have From the start of this global been committed to scaling production to meet their future volume requests. pandemic, we have had two In addition, West is also supplying primary packaging components for therapeutics used to treat COVID-19, as well as critical components that are priorities: first, ensuring the included in some of the diagnostic kit products that are being used to detect health and safety of our team COVID-19. members; and second, making We are committed to doing our part to provide for the large-scale manufacture of high-quality components required to serve customer needs for the delivery sure our customers have a reliable of a safe, effective COVID-19 vaccine. This has resulted in growing our global supply of the components that workforce to approximately 9,200 team members, expanding facility and equipment resources and shifting to 24/7 operating schedules at several sites are critical to the containment to address the demand for components associated with COVID-19.
    [Show full text]
  • Brief in Opposition to Certiorari ______
    No. 19–1451 In the Supreme Court of the United States __________ SANOFI-AVENTIS DEUTSCHLAND, GMBH, PETITIONER v. MYLAN PHARMACEUTICALS INC., RESPONDENT __________ ON PETITION FOR A WRIT OF CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT __________ BRIEF IN OPPOSITION TO CERTIORARI __________ DOUGLAS H. CARSTEN STEFFEN N. JOHNSON Wilson Sonsini Counsel of Record Goodrich & Rosati, P.C. RICHARD TORCZON 12235 El Camino Real ADAM W. BURROWBRIDGE San Diego, CA 92130 Wilson Sonsini (858) 350–2300 Goodrich & Rosati, P.C. 1700 K Street, N.W. Washington, DC 20006 (202) 973–8800 [email protected] Counsel for Respondent QUESTIONS PRESENTED 1. Whether the Federal Circuit correctly conclud- ed that Sanofi, by failing to plead or otherwise raise a nonjurisdictional Appointments Clause challenge that was pleaded and briefed by dozens of other par- ties and was the subject of extensive public commen- tary, in any brief or at any time until a letter filed two months after oral argument in that court, forfeit- ed such a challenge to the underlying Patent Trial & Appeal Board ruling at issue. 2. Whether the Federal Circuit correctly affirmed the Patent Trial and Appeal Board’s fact-bound con- clusion that Sanofi’s patents were obvious because the purported invention—adding a nonionic surfac- tant to impede insulin glargine molecules from ag- gregating during storage—simply applied a known solution to a known insulin problem. ii RELATED PROCEEDINGS The following proceedings are directly related to the case: Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland GMBH, IPR2017-01526 (P.T.A.B.), final written decision entered December 12, 2018.
    [Show full text]
  • 2019 Scientific Program Committee All Relationships Are Considered Compensated
    2019 Scientific Program Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Patents, Stock and Other Travel, Royalties, Other Expert Other Name Employment Leadership Ownership Honoraria Consulting or Advisory Role Speakers' Bureau Research Funding Accommodations, Intellectual Testimony Relationship Interests Expenses Property Monica M. Leap Syntalogic, Syntimmune Abbvie (Inst), Agenus (Inst), Astellas Pharma (Inst), AstraZeneca Bertagnolli Therapeutics (Inst), Baxalta (Inst), Bayer Health (Inst), Breast Cancer Research Foundation (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Complion (Inst), Eisai (Inst), Exelixis (Inst), Genentech (Inst), GHI Pharma (Inst), Gilead Sciences (Inst), GlaxoSmithKline (Inst), Incyte (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Leidos (Inst), Lexicon (Inst), Lilly (Inst), Matrex (Inst), Mayo Clinic (Inst), Merck (Inst), MGH (Inst), Millenium Pharamceuticals (Inst), Novartis (Inst), Patient Centered Outcomes Research Institute (PCORI) (Inst), Pfizer (Inst), Pharmacyclics (Inst), Robert Wood Johnson Foundation (Inst), Sagerock Advisors (Inst), Sanofi (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), Tesaro (Inst), Teva (Inst) Suzanne George Abbott Laboratories, AstraZeneca, Bayer, Blueprint ARIAD (Inst), Bayer (Inst), Blueprint Medicines (Inst), Deciphera UptoDate Bayer Research to Abbvie (I), Allergan (I) Medicines, Deciphera, Lilly (Inst), Novartis (Inst), Pfizer (Inst) Practice Melissa
    [Show full text]
  • Teva and Mylan
    Filed by Teva Pharmaceutical Industries Ltd. (Commission File No. 001-16174) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Mylan N.V. Commission File No.: 333-199861 Teva and Mylan Combination to Create an Industry-Leading Company, Well Positioned to Transform the Global Generics Space and Create a Unique and Differentiated Business Model, Leveraging on Its Significant Assets and Capabilities in Generics and Specialty May 5, 2015 2 Safe Harbor Statement This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and involve a number of assumptions, known and unknown risks and uncertainties that change over time and could cause future results, performance or achievements to differ materially from the results, performance or achievements expressed or implied by such forward-looking statements. These assumptions, known and unknown risks and uncertainties include, but are not limited to, those discussed in our Annual Report on Form 20-F for the year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange Commission (the “SEC”), and those relating to Mylan’s business, as detailed from time to time in Mylan’s filings with the SEC, which factors are incorporated herein by reference. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “will,” “would,” “could,” “should,” “may,” “plans” and similar expressions. All statements, other than statements of historical fact, are statements that could be deemed to be forward-looking statements, including statements about the proposed acquisition of Mylan, the financing of the proposed transaction, the expected future performance (including expected results of operations and financial guidance), and the combined company’s future financial condition, operating results, strategy and plans.
    [Show full text]
  • Faculty and Program Committee Disclosures
    Faculty and Program Committee Disclosures The following faculty and program committee members have disclosed relevant financial relationships. First Name Last Name Disclosure Founder and President of Bayou Surgical; Research Support from AstraZenica, Momotero-Gene Bryan Burt Thomas D'Amico Consultant with Scanlan Instruments; Speaker with Medtronic Consultant with AstraZeneca, BioNTech, Gritstone, Illumina, Roche; Research Support from Illumina, Varian; Shareholder (excluding diversified mutual funds) with Cibermed, Foresight Max Diehn Diagnostics Nathaniel Evans Proctor and speaker with Intuitive Surgical Consultant with Scanlan international Diego Gonzalez Rivas Research Support from AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company; Consulting fees from AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serrano, Genentech; Board Memeber with Junshi Pharmaceuticals Roy Herbst Wayne Hofstetter Research Support from Johnson and Johnson Consultant with Astra Zeneca, Daiichi-Sankyo, Imugene, Jounce Therapeutics, Merck Serono, Merck Sharpe and Dohme Corp., Michael J. Hennessy Associates, MIL PeerView, ONO Pharma, Paradigm Medical Communications, PER, Pfizer, Seattle Genetics, Zymeworks Inc.; Research Support from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli LIlly, Genentech/Roche, Merck & Co.; Shareholder (excluding diversified mutual funds) with Rgenix (stock options) Yelena Janjigian Advisor with Merck, Inc; Consultant
    [Show full text]
  • Delivering Exponential Impact
    Delivering exponential impact Impact Standardization Programs How the programs work Vizient Impact Standardization • The average term of a program is three years. Programs financially reward members’ • Nine programs require members to sign up for the program, declare the standardization efforts while reducing supplier(s) of their choice and agree to an annual purchase potential for each product variation and improving product category. These programs require aggregate compliance of 75 percent procurement processes on commonly and individual category compliance of 90 percent to earn rebates. They also purchased products. offer one* opt-out category that can be excluded from compliance Since 1996, members have earned measurement and rebate payment for that program. more than $1.5 billion in cash • The Impact Food and Impact NOVAPLUS® Pharmaceutical programs only rebates through the programs. measure compliance at the aggregate level and have no opt-out options. With 11 programs to choose from Participants in these programs who reach 80 percent aggregate compliance and built-in flexibility within each across all categories will be eligible for rebate payment from any eligible program, it’s easy to gain additional category in the program. value beyond price for your • Members have up to six months to standardize. Categories under conversion organization. are excluded from aggregate compliance calculation and are not eligible for rebates during this optional conversion period. • Rebates — averaging 3 to 6 percent of purchases — are distributed
    [Show full text]
  • Biopharmaceutical Capabilities Pharmaceutical Grade Water and Pure Steam at Maximum Uptime
    BIOPHARMACEUTICAL BIOPHARMACEUTICAL CAPABILITIES PHARMACEUTICAL GRADE WATER AND PURE STEAM AT MAXIMUM UPTIME. BIOPHARMACEUTICAL BIOPHARM EXPERIENCE THE DEEPEST EXPERIENCE AND THE BROADEST RANGE OF SOLUTIONS. With thousands of water purification systems successfully installed around the world, MECO serves leading pharmaceutical and biotech companies with over 25 million gallons of product water each day. The MECO global portfolio includes the broadest range of engineered products for purified water and WFI. This depth of global experience ensures that we understand the critical nature of maximized uptime for your operations. This is why all of our processes are built around you. Whatever your requirements—from pretreatment through production, storage and distribution, a single unit of any size or a complete integrated installation— MECO answers with the ideal combination of highly experienced engineers, state-of-the-art manufacturing and first-class service. We are relentless about finding the best solution to our customers’ needs. One that offers the highest quality of product while reducing operating “ and “ capital costs. Our entire team, from engineering to manufacturing to service, takes a studied and methodical approach to everything we do. It’s part of our culture and a key component of our DNA. CHET NUNEZ, DIRECTOR OF APPLICATIONS PHARMA AND BIOTECH CUSTOMERS IN GOOD COMPANY. At MECO, we measure ourselves by the quality of the company we keep. And when we say “keep,” we mean long-term partnerships that produce results. Scan our list of customers and you’ll see the world’s leading pharmaceutical and biotech companies, along with their trusted construction engineering firms. We pride ourselves on standards as exacting and meticulous as those required by our customers.
    [Show full text]
  • ACC.14 and TCT@ACC-I2 Program Committees Disclosures
    ACC.14 and TCT@ACC-i2 Program Committees' Disclosures of Relationships with Industry Anything Officer Ownership Data Safety Last First Middle to Attestation Speaker's Director Partnership Research Research Monitoring Name Name Name Disclose? Agreement Consulting Fees Honoraria Bureau etc. Principal Grants Salary Board Other Financial Benefit Abbott J. Dawn YES YES Pfizer Boston scientific Adams David H. YES YES Medtronic, Edwards Lifesciences, Medtronic Alexander Karen P. YES YES Gilead CytRx Amsterda Ezra A. NO YES m Ananthas Karthikeya YES YES Astellas Pharma US Inc , ubramani n GE Healthcare am Anwaruddi Saif NO YES n Applegate Robert J. YES YES Abbott Vascular St Jude Medical, Abbott Vascular Auseon Alex J. NO YES Bairey C. Noel YES YES Research Triangle Institute (RTI) Practice WISE CVD, FAMRI, NIH-SEP (grant review Study Merz Internaltional, UCSF, Kaiser, Pont RWISE, Normal Control, Section), NIH-SEP Gilead (grant review committee), Communic Microvascular Garden State AHA, Allegheny ations HGeneral Hospital, PCNA, Mayo (lectures), Foundation (lectures; Vox Media symposiums), Bryn Mawr (lectures) Hospital, Victor Chang Cardiac Research Institute (Australia, Duke (Consulting, Japense Circ Society , U of New Mexico, Emory Page 1 of 15 Anything Officer Ownership Data Safety Last First Middle to Attestation Speaker's Director Partnership Research Research Monitoring Name Name Name Disclose? Agreement Consulting Fees Honoraria Bureau etc. Principal Grants Salary Board Other Financial Benefit Ballantyne Christie M. YES YES Merck & Company, Pfizer, Abbott Pfizer, Amgen, Takeda, Genentech, Arena, Aegerion, Sanofi-Synthelabo, Novartis, Esperion, Omthera, Amarin, Novartis, Cerenis, Roche, Resverlogix, Genentech, Amarin, Amgen, Sanofi- GlaxoSmithKline, Abbott, Synthelabo, Abbott, Genzyme, Merck & Company, Eli Kowa, Regeneron Lilly, Roche, Regeneron Banerjee Subhash YES YES Covidien Medtronic Mdcare Gilead, Boston Scientific Corporation Global LLC, Corporation HygeaTel Battle Robert W.
    [Show full text]
  • Shareholder Engagement
    SHAREHOLDER ENGAGEMENT APRIL 2019 Allergan Cautionary Statements Forward Looking Statements This communication includes statements that refer to estimated or anticipated future events and are forward looking statements. We have based our forward looking statements on management’s beliefs and assumptions based on information available to our management at the time these statements are made. Such forward looking statements reflect our current perspective of our business, future performance, existing trends and information as of the date of this filing. These include, but are not limited to, our beliefs about future revenue and expense levels and growth rates, prospects related to our strategic initiatives and business strategies, including the integration of, and synergies associated with, strategic acquisitions, express or implied assumptions about government regulatory action or inaction, anticipated product approvals and launches, business initiatives and product development activities, assessments related to clinical trial results, product performance and competitive environment, and anticipated financial performance. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “plan,” “intend,” “could,” “would,” “should,” “estimate,” “continue,” or “pursue,” or the negative or other variations thereof or comparable terminology, are intended to identify forward looking statements. The statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. We caution the reader that these statements are based on certain assumptions, risks and uncertainties, many of which are beyond our control. In addition, certain important factors may affect our actual operating results and could cause such results to differ materially from those expressed or implied by forward looking statements.
    [Show full text]
  • 3M Company 3M Health Information Systems Abbott Laboratories Inc
    Vendor 3M COMPANY 3M HEALTH INFORMATION SYSTEMS ABBOTT LABORATORIES INC. ABBOTT NUTRITION ABBOTT VASCULAR DEVICES ACACIA ACCURAY INC. ACCUTYPE MEDICAL SERVICES ACCUVEIN LLC ACELL INC. ACUSIS LLC ACUTE CARE PHARMACEUTICALS ADROIT MEDICAL SYSTEMS INC ADVANCE MEDICAL DESIGNS INC. ADVANCED MEDICAL INNOVATIONS ADVANCED VASCULAR DYNAMICS ADVANCEPIERRE FOODS INC AEROSCOUT INC AESCULAP IMPLANT SYSTEMS INC. AESCULAP INC. AFFLINK INC. AGAMATRIX INC AGFA HEALTHCARE CORPORATION AIR LIQUIDE HEALTHCARE AIR MD AIRGAS INC. ALADDIN TEMP-RITE ALERE NORTH AMERICA INC. ALL MEDICAL CARE ALLCARE INC. ALLEGION ALLERGAN USA INC ALLIANCE TECH MEDICAL INC. ALLIANT HEALTHCARE ALLIED HEALTHCARE PRODUCTS INC. ALLIQUA BIOMEDICAL ALLSEATING CORPORATION ALPHA MEDICAL DISTRIBUTOR INC AMBLER SURGICAL CORP. AMBU INC. AMD-RITMED INC. AMERICAN CONTRACT SYSTEMS AMERICAN DAWN INC AMERICAN DOCTORS ONLINE LLC AMERICAN MEDICAL DEPOT AMERICAN OFFICE PRODUCTS DISTRIBUTORS AMERICAN SOLUTIONS FOR BUSINESS AMERICAN SURGICAL SPECIALTIES COMPANY AMICO CORPORATION ANCHOR PACKAGING ANDOVER HEALTHCARE INC ANGELICA TEXTILE SERVICES ANGIODYNAMICS INC ANSELL HEALTHCARE PRODUCTS INC APOLLO ENDOSURGERY APOLLO SAFETY APPLIED MEDICAL RESOURCES CORPORATION ARAMARK CLINICAL TECHNOLOGY SERVICES ARAMARK UNIFORM AND CAREER APPAREL ARCHIBALD FROZEN DESSERTS ARJOHUNTLEIGH INC ARKRAY USA ARMSTRONG RELOCATION ARROW INTERNATIONAL INC ARROW-INTECHRA LLC ARTCRAFT PROMOTIONAL CONCEPTS ARUP LABORATORIES ARYZTA LLC ASCOM US INC ASI SYSTEM INTEGRATION INC ASIAN FOOD SOLUTIONS INC ASPEN SURGICAL PRODUCTS INC. ATEECO INC ATLAS VAN LINES INC. ATT MOBILITY NATIONAL ACCOUNTS LLC AUROMEDICS PHARMA LLC AUTHENTIDATE HOLDING CORP AVID MEDICAL INC. B. BRAUN MEDICAL INC. BACTERIN INTERNATIONAL INC BAGCRAFTPAPERCON BARD ACCESS SYSTEM BARD MEDICAL DIVISION BARD PERIPHERAL VASCULAR INC BARILLA AMERICA BARRINGTON VENTURES BAUSCH LOMB SURGICAL INC. BAXTER HEALTHCARE CORPORATION BAYER HEALTHCARE BDI PHARMA BEANITOS INC BEAR FACTS ENTERTAINMENT LLC BEAVER VISITEC INTERNATIONAL INC BECKMAN COULTER INC BECTON DICKINSON AND COMPANY BELIMED INC.
    [Show full text]